WANBURY
Wanbury Limited (WANBURY) Stock Analysis
Wanbury Limited develops and markets pharmaceutical formulations in India with focus on niche therapies. It manufactures and sells branded generics through domestic marketing teams. The company operates as a listed pharma company on Indian exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹192.40
-2.07% 1W | -16.90% 52W
Market Cap
673 CR
P/E Ratio
11.8
52W High
₹358.9
52W Low
₹161.5
Div. Yield
0%
Beta
0.2
50 DMA
₹234.7
200 DMA
₹252.9
Profit Margin
8.6%
Inst. Own.
2.1%
🔥 APPROACHING RESISTANCE
🔥 APPROACHING RESISTANCE
Fundamentals
Profit & Loss
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 117 | 124 | 126 | 133 | 146 | 144 | 146 | 139 | 131 | 161 | 133 | 172 | 163 |
| Expenses | 120 | 118 | 119 | 119 | 133 | 127 | 124 | 121 | 120 | 141 | 120 | 142 | 139 |
| Operating Profit | -3 | 6 | 6 | 14 | 13 | 17 | 21 | 18 | 11 | 20 | 14 | 30 | 24 |
| OPM % | -2.6% | 4.5% | 5% | 11% | 9% | 12% | 15% | 13% | 8% | 12% | 10% | 17% | 15% |
| Other Income | 2 | 1 | 0 | -3 | 1 | 1 | 1 | 26 | 1 | 2 | 1 | 2 | 0 |
| Interest | 3 | 4 | 7 | 8 | 6 | 8 | 8 | 7 | 8 | 10 | 10 | 9 | 8 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Profit before tax | -7 | -1 | -3 | 1 | 5 | 7 | 10 | 34 | 1 | 8 | 1 | 19 | 14 |
| Tax % | -3% | 25% | 8% | -11% | 6% | -2% | -0% | 1% | 0% | 2% | 5% | -6% | 1% |
| Net Profit | -7 | -1 | -3 | 1 | 5 | 7 | 10 | 34 | 1 | 8 | 1 | 20 | 13 |
| EPS in Rs | -2.21 | -0.27 | -1.00 | 0.31 | 1.43 | 2.25 | 3.14 | 10.27 | 0.32 | 2.45 | 0.37 | 6.18 | 4.10 |
| Metric | Sep 201418m | Mar 20156m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 661 | 250 | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 485 | 557 | 600 | 630 |
| Expenses | 637 | 228 | 387 | 414 | 438 | 375 | 344 | 374 | 475 | 459 | 484 | 520 | 542 |
| Operating Profit | 25 | 21 | 33 | 19 | -68 | 16 | 23 | 18 | 36 | 26 | 73 | 80 | 88 |
| OPM % | 3.7% | 9% | 8% | 4.3% | -18% | 4.1% | 6% | 4.7% | 7% | 5% | 13% | 13% | 14% |
| Other Income | -78 | 6 | 0 | 90 | 76 | 9 | 84 | 2 | 77 | -3 | 26 | -0 | 5 |
| Interest | 48 | 19 | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 29 | 37 | 37 |
| Depreciation | 23 | 5 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 | 14 |
| Profit before tax | -125 | 4 | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 56 | 30 | 42 |
| Tax % | 2% | 28% | 0% | 1% | -1% | -1% | 0% | 2% | -0% | 1% | 1% | -3% | |
| Net Profit | -128 | 3 | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 56 | 31 | 43 |
| EPS in Rs | -63.95 | 1.60 | -3.58 | 26.71 | -13.49 | -10.48 | 25.79 | -5.04 | 24.94 | -3.18 | 17.09 | 9.32 | 13.10 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 5.0% | 10.0% | 9.0% |
| Profit CAGR | 80.0% | 31.0% | 26.0% |
Shareholding Pattern
Promoters39.63%
FIIs1.59%
Public58.79%
Promoters43.09%
FIIs0.82%
Public56.08%
Promoters43.08%
FIIs0.72%
Public56.21%
Promoters43.01%
FIIs0.59%
Public56.39%
Promoters43.01%
FIIs0.89%
DIIs0.06%
Public56.04%
Promoters39.84%
Public60.16%
Promoters39.79%
FIIs0.18%
Public60.02%
Promoters39.76%
FIIs1.55%
Public58.68%
Promoters43.01%
FIIs0.59%
Public56.39%
Promoters43.01%
FIIs0.89%
DIIs0.06%
Public56.04%
WANBURY
Holdings Analysis
Key strengths & risk signals
56
Overall
50
Fundamental
62
Technical
Risks (4)
TOO MUCH PUBLIC HOLDING! 60.16% public ownership - higher volatility risk.
WEAK POSITION! Current price (186.3) is below both moving averages.
WEAK YEAR! Stock declined 17.7% in the last year.
WEAK! Trading at 12.6% of 52W range - near yearly lows.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
OVERSOLD! RSI at 27.3 - potential bounce opportunity.
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 9 up days, 21 down days. Avg volume on up days: 310,663 vs down days: 225,872. Ratio: 1.38x
Fundamental & Technical Analysis
52Overall
50Fundamental
55Technical
Fundamental Breakdown
Growth Quality
10/30
Revenue CAGR: 8.9% (MODERATE, 8/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
3/10
LOW MARGIN! 8.6% profit margin - thin profits.
PEG Valuation
9/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 60.16% public ownership - higher volatility risk.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (234.7) is below 200-day average (252.9) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (192.4) is below both moving averages.
Trend Pattern
10/20
AT RESISTANCE! Stock is at key resistance level.
52W Performance
2/10
WEAK YEAR! Stock declined 16.9% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 307,262 vs down days: 231,354. Ratio: 1.33x
RSI
4/5
APPROACHING OVERSOLD! RSI at 33.8 - watch for reversal.
52W Range
1/5
WEAK! Trading at 15.7% of 52W range - near yearly lows.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 2.1% (1 week), 13.6% (1 month), 42.1% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WANBURY | ₹192.40 | 11.8 | 8.6% | 8.9% | – | -16.9% | 52 | APPROACHING RESISTANCE | -76.3% | -85.3% | +1.5% | +0.6% |
| AMANTA | ₹183.40 | 44.1 | 5.0% | 3.3% | – | +50.9% | 58 | BREAKDOWN | -5.7% | -40.0% | +5.4% | -10.6% |
| VALIANTLAB | ₹134.70 | 47.9 | 5.2% | -10.7% | – | +48.0% | 64 | BREAKDOWN | +1,072.2% | +1,072.2% | +146.4% | +25.3% |
| ZIMLAB | ₹144.80 | 176.5 | 0.9% | -2.5% | -37.9% | +112.5% | 58 | CONSOLIDATING UP | +110.5% | -208.1% | +31.2% | -10.5% |
| KILITCH | ₹230.40 | 26.2 | 12.7% | 19.2% | 42.4% | +23.4% | 84 | BREAKOUT | -3.3% | -80.0% | +4.2% | -49.9% |
| ANUHPHR | ₹82.60 | 18.7 | 5.7% | 13.5% | 4.3% | +5.1% | 65 | BREAKDOWN | +37.3% | -2.6% | +3.9% | -4.1% |
| ALBERTDAVD | ₹831.00 | 21 | 6.2% | -1.1% | – | +1.5% | 51 | APPROACHING SUPPORT | +305.1% | -249.5% | +43.5% | +17.9% |
| MEDICAMEQ | ₹284.40 | 38.4 | 4.7% | 12.0% | -13.4% | -6.8% | 57 | CONSOLIDATING DOWN | -4.5% | -46.2% | +11.4% | -21.0% |
Data from TradeAlone · Updated daily
WANBURY News
Wanbury Limited (wanbury): Receives 9 ‘no DMF Deficiency’ Letters from Usfda, Expands Metformin Business Globally2026-10-16Wanbury Limited Launches Berrysoft™ Baby Product Range, Marks Strategic Entry in Paediatric Dermatology2026-10-12Wanbury Limited (wanbury) Delivers 117% Yoy PAT Growth in FY26; EPS More Than Doubles2026-06-02
